Biomarin Pharmaceutical (BMRN) Accounts Payables (2009 - 2026)

Biomarin Pharmaceutical has disclosed Accounts Payables across 18 years of filings, most recently posting $793.2 million for Q1 2026.

• Quarterly Accounts Payables rose 26.26% year-over-year to $793.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $793.2 million (up 26.26% YoY) and the FY2025 annual result came in at $759.0 million, up 25.05% from the prior year.
• Accounts Payables climbed to $793.2 million in Q1 2026, from $759.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $798.4 million in Q3 2025 and troughed at $426.4 million in Q1 2022.
• A 5-year average of $625.1 million and a median of $607.0 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables soared 40.29% — and 2024, when it dropped 11.15%.
• Tracing BMRN's Accounts Payables over 5 years: stood at $573.0 million in 2022, then advanced by 19.23% to $683.1 million in 2023, then slipped by 11.15% to $607.0 million in 2024, then climbed by 25.05% to $759.0 million in 2025, then gained by 4.5% to $793.2 million in 2026.
• Business Quant data shows BMRN's Accounts Payables at $793.2 million in Q1 2026, $759.0 million in Q4 2025, and $798.4 million in Q3 2025.